Inventiva (NASDAQ:IVA) Sees Large Volume Increase Following Analyst Upgrade

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw unusually-high trading volume on Friday after Truist Financial raised their price target on the stock from $13.00 to $18.00. Truist Financial currently has a buy rating on the stock. Approximately 1,016,893 shares traded hands during trading, an increase of 21% from the previous session’s volume of 837,308 shares. The stock last traded at $3.5350 and had previously closed at $3.46.

A number of other brokerages also recently issued reports on IVA. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Guggenheim boosted their target price on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $15.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IVA. Propel Bio Management LLC purchased a new stake in Inventiva in the fourth quarter worth about $4,650,000. Seven Fleet Capital Management LP purchased a new position in Inventiva during the first quarter valued at approximately $1,111,000. Eventide Asset Management LLC purchased a new position in Inventiva during the fourth quarter valued at approximately $1,155,000. NEXTBio Capital Management LP bought a new position in Inventiva in the fourth quarter worth approximately $6,039,000. Finally, Engineers Gate Manager LP lifted its holdings in Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after buying an additional 43,280 shares during the period. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Trading Up 4.2%

The business has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $4.67.

Inventiva (NASDAQ:IVA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million during the quarter. As a group, equities analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current year.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.